Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Severe haematological complications during treatment with natalizumab.
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
A qualitative exploration of the impact of a 12-week group exercise class for those moderately affected with multiple sclerosis.
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia.
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
Microbial colonization influences early B-lineage development in the gut lamina propria.
Biologics at Novartis
Quantitative assessment of multiple sclerosis using inertial sensors and the TUG test.
Focused suggestion with somatic anchoring technique: rapid self-hypnosis for pain management.
Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam.
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.
Placebo? no thanks, it might be bad for me!
Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients.
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation.
Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions.
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning.
An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis.

Pages